Reply to Gantt et al., “Higher Expectations for a Vaccine To Prevent Congenital Cytomegalovirus Infection”

Abstract

Gantt et al. ([1][1]) make useful and valid points about the importance of developing a cytomegalovirus (CMV) vaccine that targets reduction in congenital infections in seropositive women, in addition to preventing infection (with subsequent transmission) in seronegative patients. We agree that